ArticleBlood science (Baltimore, Md.)2026
Transcriptomics-based multi-omics approach for optimizing risk stratification in acute myeloid leukemia.
Article in Blood science (Baltimore, Md.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute myeloid leukemia (AML) is a subtype of hematopoietic neoplasm affecting myeloid cells in blood and bone marrow. Molecular subtyping of AML provides in-depth insights into disease pathogenesis, facilitating clinical diagnostics and therapeutic management. While current molecular screening is mainly established on DNA-based approaches, including targeted sequencing of gene panels and polymerase chain reaction (PCR)-based fusion gene detection, transcriptome-based RNA-seq has gained increasing attention for its potential in improving molecular subtyping as well as in facilitating prognostic prediction and therapeutic selection. In this study, we aimed to identify transcriptomic signatures in molecular genotyping and risk stratification in a cohort of 125 patients with AML excluding those harboring
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.